Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) FCF Margin (2018 - 2025)

Cue Biopharma's FCF Margin history spans 8 years, with the latest figure at 419.92% for Q3 2025.

  • For Q3 2025, FCF Margin fell 19432.0% year-over-year to 419.92%; the TTM value through Sep 2025 reached 420.03%, down 1794.0%, while the annual FY2024 figure was 391.89%, 33600.0% up from the prior year.
  • FCF Margin for Q3 2025 was 419.92% at Cue Biopharma, down from 116.56% in the prior quarter.
  • Across five years, FCF Margin topped out at 116.56% in Q2 2025 and bottomed at 49665.38% in Q2 2022.
  • The 5-year median for FCF Margin is 573.03% (2024), against an average of 4282.04%.
  • The largest annual shift saw FCF Margin plummeted -4929948bps in 2022 before it skyrocketed 4891549bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 128.96% in 2021, then plummeted by -5300bps to 6963.58% in 2022, then skyrocketed by 91bps to 602.09% in 2023, then increased by 5bps to 572.97% in 2024, then rose by 27bps to 419.92% in 2025.
  • Per Business Quant, the three most recent readings for CUE's FCF Margin are 419.92% (Q3 2025), 116.56% (Q2 2025), and 1976.72% (Q1 2025).